Mike Zaman's  Instablog

Mike Zaman
Send Message
  • La Jolla Pharma (LJPC) Galectin-3 Inhibitor Positive Top-Line Results, Ship Finance (SFL) Settles Claim 0 comments
    Mar 11, 2014 6:48 AM | about stocks: LJPC, SFL

    https://staticseekingalpha.a.ssl.fastly.net/uploads/2014/3/11/saupload_ljpc.jpg La Jolla Pharmaceutical Co. (NASDAQ:LJPC)

    The main function of the kidneys is to remove wastes and excess water from the body.

    Did you know that a person can lose up to 90% of their kidney function before experiencing any symptoms?

    Chronic kidney disease is the slow loss of kidney function over time. It slowly gets worse over time. In the early stages, there may be no symptoms. The loss of function usually takes months or years to occur. It may be so slow that symptoms do not appear until kidney function is less than one-tenth of normal.

    The final stage of chronic kidney disease is called end-stage renal disease. At this stage, the kidneys are no longer able to remove enough wastes and excess fluids from the body. The patient needs dialysis or a kidney transplant.

    Chronic kidney disease and end-stage renal disease affect more than 2 out of every 1,000 people in the United States.

    The two main causes of chronic kidney disease are diabetes and high blood pressure, which are responsible for up to two-thirds of the cases.

    LJPC reported positive top-line results from its Phase 2 clinical trial of GCS-100 in chronic kidney disease. The trial met its primary efficacy endpoint of a statistically significant improvement in kidney function. LJPC's GCS-100 was well-tolerated

    LJPC's GCS-100 is a high molecular weight, complex polysaccharide that inhibits galectin-3, a molecule believed to play a central role in tissue fibrosis, or scarring. GCS-100 currently is in Phase 2 clinical development for chronic kidney disease and also has been shown to be therapeutically active in preclinical models of other diseases where tissue fibrosis plays a central role, such as nonalcoholic steatohepatitis.


    LJPC is focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer.

    More about La Jolla Pharmaceutical Co. (LJPC) at www.ljpc.com.


    https://staticseekingalpha.a.ssl.fastly.net/uploads/2014/3/11/saupload_sfl.jpg Ship Finance International Limited (NYSE:SFL)

    SFL reported the settlement of a claim relating to four Handysize dry bulk carriers which were redelivered to the company in 2012, before the final maturity of their charters.

    According to the company, a significant portion of the settlement amount has been paid to SFL in cash already, with the remaining amount to be paid in installments over the next three quarters. SFL expects to book a gain of approximately $25 million relating to the settlement.

    SFL also announced the agreement to acquire two 5,800 teu post-panamax container vessels built in 2001/2002 in combination with long-term charters.

    The vessels are expected to be delivered to SFL over the course of the next few weeks, and the annual EBITDA contribution is estimated to be approximately $5.5 million on average during the charter period. The charters include a purchase option with profit share after 5 years.


    SFL is a major vessel owning company. Its fleet is one of the largest in the world and the Company has a substantial portfolio of long term fixed charters with an average tenor of approximately 10 years. Stability in both charter revenues and operating costs supports SFL's long term distribution capacity.

    More about Ship Finance International Limited (SFL) at www.shipfinance.org


    Read Full Disclaimer at www.pennyomega.com/disclaimer

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Stocks: LJPC, SFL
Back To Mike Zaman's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.